Pasquale Vergara

Dr. Pasquale Vergara

IRCCS Ospedale San Raffaele, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Heart Rhythm
Verified
Journal Article
Closed access
RTRoderick Tung
Roderick Tung
MVMarmar Vaseghi
Marmar Vaseghi
DFDavid S. Frankel
David S. Frankel
PVPasquale Vergara
Pasquale Vergara
LBLuigi Di Biase
Luigi Di Biase
KSKalyanam Shivkumar
Kalyanam Shivkumar

4 April 2012 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
PVPasquale Vergara
Pasquale Vergara
NTNicola Trevisi
Nicola Trevisi
ARAnnalisa Ricco
Annalisa Ricco
FPFrancesco Petracca
Francesco Petracca
FBFrancesca Baratto
Francesca Baratto
PBPaolo DELLA Bella
Paolo DELLA Bella

1 October 2011 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PBPaolo Della Bella
Paolo Della Bella
JBJosep Brugada
Josep Brugada
KZKatja Zeppenfeld
Katja Zeppenfeld
JMJose Merino
Jose Merino
PNPetr Neuzil
Petr Neuzil
AWAdrianus P. Wijnmaalen
Adrianus P. Wijnmaalen
Background—: The purpose of this study was to describe the epicardial percutaneous ablation experience of 6 European high-volume ventricular tachycardia (VT) ablation centers. Methods and Results—: Data from 218 patients with coronary artery disease (CAD, n=85 [39.0%]), idiopathic dilated of patients with idiopathic VT cardiomyopathy (IDCM, n=67 [30.7%]), arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARCD/C, n=13 [6%]), hypertrophic cardiomyopathy (HCM, n=5 [2.3%]), and absence of structural heart disease (n=48 [22%]) undergoing epicardial subxyphoid access for VT ablation were collected. The epicardial approach was attempted as first-line treatment in 78 patients (35.8%). Acute prevention of VT inducibility was obtained in 156 patients (71.6%). There were no procedure-related deaths. Cardiac tamponade occurred in 8 patients, and abdominal hemorrhage in 1 patient. Six patients died of electrical storm recurrence within 48 hours from the procedure. After a mean follow-up of 17.3±18.2 months, 60 patients (31.4%) presented with VT recurrence (39.3% of IDCM patients; 34.7% of CAD patients; 30.8% of ARVD/C patients; 25% of HCM patients; 17.1% of patients with idiopathic VT). Twenty patients (10.4%) died during follow-up (12 of heart failure, 2 of cardiac arrest, and 6 of extracardiac causes). Conclusions—: In experienced centers, epicardial ablation of VT has an acceptable risk and favorable outcome. In selected patients, it is reasonable to consider as a first-line ablation approach.

2 April 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
PBPaolo Della Bella
Paolo Della Bella
FBFrancesca Baratto
Francesca Baratto
DTDimitris Tsiachris
Dimitris Tsiachris
NTNicola Trevisi
Nicola Trevisi
PVPasquale Vergara
Pasquale Vergara
GMGiuseppe Maccabelli
Giuseppe Maccabelli
Background—: We investigated the impact of catheter ablation on ventricular tachycardia (VT) recurrence and survival in a large number of patients with structural heart disease treated in the setting of a dedicated multiskilled unit. Methods and Results—: Since January 2007, we have implemented a multidisciplinary model, aiming for a comprehensive management of VT patients. Programmed ventricular stimulation was used to assess acute outcome. Primary end points were VT recurrence and the occurrence of cardiac and sudden cardiac death. Overall, 528 patients were treated by ablation (634 procedures; 1–4 procedures per patient). Among 482 tested with programmed ventricular stimulation after the last procedure, a class A result (noninducibility of any VT) was obtained in 371 patients (77%), class B (inducibility of nondocumented VT) in 12.4%, and class C (inducibility of index VT) in 10.6%. After a median follow-up time of 26 months, VT recurred in 164 (34.1%) of 472 patients. VT recurrence was documented in 28.6% of patients with a class A result versus 39.6% of patients with class B and 66.7% with class C result (log-rank P <0.001). The incidence of cardiac mortality was lower in class A patients than in those with class B and class C (8.4% versus 18.5% versus 22%, respectively; log-rank P =0.002). On the basis of multivariate analysis, postprocedural inducibility of index VT was independently associated both with VT recurrence (hazard ratio, 4.030; P <0.001) and with cardiac mortality (hazard ratio, 2.099; P =0.04). Conclusions—: Within a dedicated VT unit, catheter ablation prevents long-term VT recurrences, which may favorably affect survival in a large number of patients who have VT.

1 June 2014 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
TOTeresa Oloriz
Teresa Oloriz
John SilberbauerJohn Silberbauer
John Silberbauer
GMGiuseppe Maccabelli
Giuseppe Maccabelli
HMHiroya Mizuno
Hiroya Mizuno
FBFrancesca Baratto
Francesca Baratto
PBPaolo Della Bella
Paolo Della Bella
Background—: The aim was to relate distinct scar distributions found in nonischemic cardiomyopathy with ventricular tachycardia (VT) morphology, late potential distribution, ablation strategy, and outcome. Methods and Results—: Eighty-seven patients underwent catheter ablation for drug-refractory VT. Based on endocardial unipolar voltage, 44 were classified as predominantly anteroseptal and 43 as inferolateral. Anteroseptal patients more frequently fulfilled diagnostic criteria for dilated cardiomyopathy (64% versus 36%), associated with more extensive endocardial unipolar scar (41 [22–83] versus 9 [1–29] cm 2 ; P <0.001). Left inferior VT axis was predictive of anteroseptal scar (positive predictive value, 100%) and right superior axis for inferolateral (positive predictive value, 89%). Late potentials were infrequent in the anteroseptal group (11% versus 74%; P <0.001). Epicardial late potentials were common in the inferolateral group (81% versus 4%; P <0.001) and correlated with VT termination sites (κ=0.667; P =0.014), whereas no anteroseptal patient had an epicardial VT termination ( P <0.001). VT recurred in 44 patients (51%) during a median follow-up of 1.5 years. Anteroseptal scar was associated with higher VT recurrence (74% versus 25%; log-rank P <0.001) and redo procedure rates (59% versus 7%; log-rank P <0.001). After multivariable analysis, clinical predictors of VT recurrence were electrical storm (hazard ratio, 3.211; P =0.001) and New York Heart Association class (hazard ratio, 1.608; P =0.018); the only procedural predictor of VT recurrence was anteroseptal scar pattern (hazard ratio, 5.547; P <0.001). Conclusions—: Unipolar low-voltage distribution in nonischemic cardiomyopathy allows categorization of scar pattern as inferolateral, often requiring epicardial ablation mainly based on late potentials, and anteroseptal, which frequently involves an intramural septal substrate, leading to a higher VT recurrence.

1 January 2018 in Heart Rhythm
Verified
Journal Article
Closed access
PVPasquale Vergara
Pasquale Vergara
RTRoderick Tung
Roderick Tung
MVMarmar Vaseghi
Marmar Vaseghi
CBChiara Brombin
Chiara Brombin
DFDavid Frankel
David Frankel
PBPaolo Della Bella
Paolo Della Bella